CLAIMS

We claim:

1. Crystalline form II of cabergoline having the IR spectrum of Figure 3.

2. Crystalline form II of cabergoline according to claim 1 which is anhydrous, non-solvated and has a percentage purity greater than 85%.

3. Crystalline form II of cabergoline according to claim 1 which is anhydrous, non-solvated and has a percentage purity greater than 98%.

4. A pharmaceutical composition which comprises an effective amount of crystalline Form II as defined in claim 1 in combination with one or more pharmaceutically acceptable carriers, excipients, diluents or adjuvants.

5. A process for producing cabergoline Form II as defined in claim 1 which process comprises crystallisation of the desired form II from a solution of raw carbergoline in an organic solvent at a low temperature.

6. A process according to claim 5 in which the organic solvent is a ketone, an acetal, a linear ether, an ester or a mixture thereof.

7. A process according to claim 5 in which the solvent is diethyl ether or methyl tert-butyl ether.

8. A process for producing cabergoline Form II as defined in claim 1, which process comprises subjecting a mixture of cabergoline forms I and II in a solvent at a temperature below about 30°C to a slurry procedure.

9. A process according to claim 8 in which the solvent is diethyl ether or n-hexane.

10. Crystalline form II of cabergoline having the DSC curve of Figure 2.

11. Crystalline form II of cabergoline according to claim 10 which is anhydrous, non-solvated and has a percentage purity greater than 85%.

12. Crystalline form II of cabergoline according to claim 1 which is anhydrous, non-solvated and has a percentage purity greater than 98%.

13. A pharmaceutical composition which comprises an effective amount of crystalline Form II as defined in Claim 10 in combination with one or more pharmaceutically acceptable carriers, excipients, diluents or adjuvants.

14. A process for producing cabergoline Form II as defined in Claim 10, which process comprises crystallisation of the desired form II from a solution of raw carbergoline in an organic solvent at a low temperature.

15. A process according to claim 14 in which the organic solvent is a ketone, an acetal, a linear ether, an ester or a mixture thereof.

16. A process according to Claim 14 in which the solvent is diethyl ether or methyl tert-butyl ether.

17. A process for producing cabergoline Form II as defined in Claim 10, which process comprises subjecting a mixture of cabergoline forms I and II in a solvent at a temperature below about 30°C to a slurry procedure.

18. A process according to claim 17 in which the solvent is diethyl ether or n-hexane.